These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33853558)

  • 1. Humanized anti-DEspR IgG4
    Gromisch CM; Tan GLA; Pasion KA; Moran AM; Gromisch MS; Grinstaff MW; Carr FJ; Herrera VLM; Ruiz-Opazo N
    BMC Cancer; 2021 Apr; 21(1):407. PubMed ID: 33853558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DEspR roles in tumor vasculo-angiogenesis, invasiveness, CSC-survival and anoikis resistance: a 'common receptor coordinator' paradigm.
    Herrera VL; Decano JL; Tan GA; Moran AM; Pasion KA; Matsubara Y; Ruiz-Opazo N
    PLoS One; 2014; 9(1):e85821. PubMed ID: 24465725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells.
    Wang X; Liu Q; Hou B; Zhang W; Yan M; Jia H; Li H; Yan D; Zheng F; Ding W; Yi C; Hai Wang
    PLoS One; 2013; 8(9):e73942. PubMed ID: 24040121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confirmation of translatability and functionality certifies the dual endothelin1/VEGFsp receptor (DEspR) protein.
    Herrera VL; Steffen M; Moran AM; Tan GA; Pasion KA; Rivera K; Pappin DJ; Ruiz-Opazo N
    BMC Mol Biol; 2016 Jun; 17(1):15. PubMed ID: 27301377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
    Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
    Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
    Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
    Ying J; Tsujii M; Kondo J; Hayashi Y; Kato M; Akasaka T; Inoue T; Shiraishi E; Inoue T; Hiyama S; Tsujii Y; Maekawa A; Kawai S; Fujinaga T; Araki M; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
    Int J Oncol; 2015 Apr; 46(4):1551-9. PubMed ID: 25625841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.
    Recio-Boiles A; Ilmer M; Rhea PR; Kettlun C; Heinemann ML; Ruetering J; Vykoukal J; Alt E
    Oncotarget; 2016 Mar; 7(9):9890-906. PubMed ID: 26840266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine.
    Forciniti S; Dalla Pozza E; Greco MR; Amaral Carvalho TM; Rolando B; Ambrosini G; Carmona-Carmona CA; Pacchiana R; Di Molfetta D; Donadelli M; Arpicco S; Palmieri M; Reshkin SJ; Dando I; Cardone RA
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyphenols from marine brown algae target radiotherapy-coordinated EMT and stemness-maintenance in residual pancreatic cancer.
    Aravindan S; Ramraj SK; Somasundaram ST; Herman TS; Aravindan N
    Stem Cell Res Ther; 2015 Sep; 6(1):182. PubMed ID: 26395574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
    Cioffi M; Dorado J; Baeuerle PA; Heeschen C
    Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
    Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-DEspR antibody treatment improves survival and reduces neurologic deficits in a hypertensive, spontaneous intracerebral hemorrhage (hsICH) rat model.
    Herrera VLM; Gromisch CM; Decano JL; Pasion KA; Tan GLA; Hua N; Takahashi CE; Greer DM; Ruiz-Opazo N
    Sci Rep; 2023 Feb; 13(1):2703. PubMed ID: 36792616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs.
    Ning X; Du Y; Ben Q; Huang L; He X; Gong Y; Gao J; Wu H; Man X; Jin J; Xu M; Li Z
    Cell Cycle; 2016; 15(3):403-12. PubMed ID: 26709750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.